Latest news, reports, and more from the RedChip Nation.
RedChip.com     April 12, 2018     Contact    
 
 
10-Year Exclusive Deal with Kathy Ireland Positions Level Brands (NYSE American: LEVB) for Profitability and Strong Growth
 

Licensing is big business.


The world's largest licensors generated $272 billion in retail sales in 2016.


Brands like Disney, Warner Bros., Universal, and Hasbro are the industry heavyweights, commanding a significant share of the market.


We've recently discovered a company in an exclusive 10-year agreement with kathy ireland Worldwide, the 26th-largest licensor globally (tied with Ferrari at $2.6 billion annually).


The company, Level Brands (NYSE American: LEVB), went public through a Regulation A+ offering in November 2017. It's only the second such IPO to list and trade on the NYSE American.


As a Reg A+ offering, which raised the maximum $12 million available, it flew under the radar of much of Wall Street, which has created a compelling opportunity for investors.


Priced at $6 per share, the stock has pulled back in the months since its IPO, with shares trading near $4 in recent days.


It's mispriced opportunities like this that can create big wins for investors.


Since going public, the company reported triple-digit growth for the first quarter of fiscal 2018, with sales up an impressive 244% year-over-year. Gross profit surged 1,138% in the period.


Yet the stock has traded down.


Even if it just traded back to its IPO price, investors could see nearly 50% returns. With a regular stream of announcements of new deals, such as the company's $32 million, 10-year deal with CBD-manufacturer Isodiol, the upside could be significantly more.


Licensing Leader Kathy Ireland Serves as Chief Brand Strategist


Famed supermodel turned entrepreneur Kathy Ireland serves as Level Brands' Chairman Emeritus and Chief Brand Strategist.


Her wealth of experience gives Level Brands a strong competitive advantage and the potential for rapid growth.


Low Overhead, High Margins


As a licensing company, Level Brands is a non-capital-intensive business with very limited overhead and virtually no inventory.


Composed of a talented team focused on establishing new brand-management deals and expanding distribution for each of its four divisions, like the recently announced Riley Rose deal signed by its Beauty & Pin-Ups division, the company generates impressive margins, with gross margins expected in the 70%-80% range.


Strong Fundamentals


Thanks to a recent start and an influx of cash from its IPO, Level Brands has a strong balance sheet, with zero long-term debt and approximately $9 million in cash.


With its low overhead and high-margin business model combined with an impressive and growing list of licensing deals and distribution channels, Level Brands is well-positioned for solid growth in the quarters ahead.


The company generates a combination of upfront fees, in the form of cash or equity as well as ongoing royalties on sales for each of its licensing deals. Over time, this could easily lead to exponential growth, leading to a substantially higher valuation.


Kathy Ireland Discusses Relationship with Level Brands


Hear directly from Kathy Ireland herself as she discusses the Level Brands opportunity: https://levelbrands.com/
kathyirelandlevelbrands/


With triple-digit growth, a growing roster of licensing deals, and the support and experience of Kathy Ireland, it's only a matter of time before more investors catch wind of the Level Brands opportunity.


Those who get shares early could see a big reward in the months ahead.


Sign up for news alerts on Level Brands today to stay informed of the latest developments.


Disclosure

(Level Brands (NYSE: LEVB) is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services. )


  536 words
 
 
 
 
 
Digital Ally (NASDAQ: DGLY) to Discuss 2017 Results & Patent Litigation Status in April 13 Conference Call
 

Digital Ally (NASDAQ: DGLY), which develops, manufactures, and markets advanced digital-technology products for law enforcement, homeland security, and commercial security, today announced that it will host an investor conference on Fri., April 13, 2018 at 11:15 a.m. ET. There, it will discuss its operating results for the fourth quarter and year ended Dec. 31, 2017 as well as the status of its patent-infringement litigation against Axon Enterprise Inc. ("Axon," formerly known as TASER International Inc.) and Enforcement Video, LLC d/b/a WatchGuard Video (WatchGuard).


Event Details:
Dial-In #: (844) 761-0863 Conference ID: 6874236
Friday, April 13 at 11:15 a.m. ET


Key Quote: "Axon has continued to build its line of Axon camera products on the back of Digital's patented auto-activation technology," said Digital's CEO, Stanton E. Ross. "It is frustrating to see our technology being used by a competitor to generate such massive sales, but we are confident the jury in Kansas will put an end to this willful infringement and reward Digital for its industry-changing auto-activation technology."


What's Next:: The last update DGLY provided related to its patent litigation against Axon Enterprise (NASDAQ: AAXN). The Company expressed confidence in its ability to prevail. In 2016 and 2017, Axon's public filings show $37,848,000 in net sales of Axon Body and Axon Flex, the cameras under scrutiny. Net sales of Evidence.com, which drives the sales of the products under scrutiny and is sold with nearly every camera, totaled $69,958,000 in those years. Both products are covered in DGLY's lawsuit. With a favorable update on the upcoming call, the shares could see a big boost.


Disclosure

(Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.)

  262 words
 
 
 
 
 
Sorrento (NASDAQ: SRNE) & Celularity Begin Screening Multiple Myeloma Patients for Phase 1 CAR-T Program
 

Sorrento Therapeutics Inc. (NASDAQ: SRNE) and Celularity Inc announced last week that the companies have started screening patients for its leading CD38 chimeric antigen receptor (CAR) T cell therapy drug-development program, following FDA review allowing clinical trial initiation.


Why It Matters: The companies’ CD38 CAR-T program is their most advanced program targeting this difficult-to-treat condition. This trial is currently the only active U.S.-based clinical trial targeting CD38 using a CAR T cell therapy.


Key Quote: "This represents a major milestone for Sorrento and Celularity that clearly demonstrates our keen focus on advancing our therapeutics assets as well as our ability to deliver on the timelines we previously communicated.” Dr. Henry Ji, Chairman and CEO


What's Next:: As milestones are reached, look for ongoing updates, including patient enrollment and eventually data readouts. SRNE shares have reacted well to news in the past, so any positive achievements could send shares even higher.


Disclosure

(Sorrento Therapeutics, Inc. (SRNE) is a client of RedChip Companies, Inc. SRNE agreed to pay RedChip Companies, Inc., a cash fee three (3) months of RedChip investor awareness services. and consulting services.)

  150 words
 
 
 
 
 
TapImmune (NASDAQ: TPIV) Reports Year-end 2017 Corporate & Clinical Update
 

TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, provided a business update for the 4Q17 and FY17.


Recent corporate and clinical developments:  

  1. Published long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200
  2. Commenced dosing in 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC
  3. Enhanced IP portfolio for PolyStart™ technology, expanding to cover any polypeptide sequences comprising poly-antigen arrays (PAAs)
  4. Appointed Dr. Richard Kenney Acting Chief Medical Officer

Upcoming Anticipated Milestones FY18-FY19:

  1. Q3 2018: Report interim immune response data from ongoing Phase 2 TNBC
  2. 2H 2018: Report interim results from ongoing Phase 2 study of TPIV200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
  3. 2018: Mayo Clinic to initiate Phase 1b/2a study of TPIV100 in women with HER2/neu+ ductal carcinoma in situ (DCIS) breast cancer
  4. 1Q 2019: Report interim safety and futility results from Phase 2 ovarian cancer study

Key Quote: Peter Hoang, President and CEO of TapImmune: “Throughout 2017, we made significant advances toward achieving our goals and reaching our milestones. We recently announced the publication of new clinical data for our multi-epitope T-cell vaccine targeting folate receptor alpha, TPIV200, in patients with ovarian and breast cancer.”


The Backstory: TapImmune is in four active Phase 2 clinical trials (six clinical trials in total) in the $100+ billion market for immunotherapy cancer drugs. The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health), and much of the growth is being driven by constant innovations in cancer immunotherapy. Currently, the company is advancing its robust mid-stage clinical pipeline focused on breast and ovarian cancer.


Disclosure

(TapImmune Inc. (TPIV) is a client of RedChip Companies, Inc. TPIV agreed to pay RedChip Companies, Inc., a monthly cash fee of RedChip investor awareness services. and consulting services. )

  290 words
 
 
 
 
 
Spectrum Global's (OTC: SGSI) Telecom Contract Pipeline Expands Rapidly in March
 

After announcing more than $2 million in new client orders in March in back to back press releases, Spectrum Global Solutions (OTC: SGSI) continues to impress, starting off April with another $860,000 in new contract awards.  A leading provider of telecom engineering and infrastructure services in North America and the Caribbean, SGSI, through its wholly-owned subsidiaries, has built an impressive client roster of major service providers and enterprise customers and is ideally positioned for continued growth.


Why It Matters: With the rollout of 5G and the introduction of new communications-heavy technologies like the internet of things, the need for engineering and infrastructure services in telecom and enterprise markets should remain robust for many years to come. SGSI has proven itself a player in this space, and the recent contract wins show strong sales acceleration. Based on recent news, the Company has booked nearly $6.5 million in new contracts year-to-date through the first week of April. Nearly half of that has been announced in the past few weeks.


Key Quote: "Year over year, the Company is outpacing last year's sales for the same period. We anticipate seeing continued growth during 2018 as carrier and enterprise demand increases to support new technology and prepare structures for those deployments." - Roger Ponder, CEO


What's Next? With favorable industry trends underpinning its core telecom services business, it's likely we'll see a steady flow of new contract win announcements in the months ahead. Right now, the stock trades for a market cap of under $3 million - less than the sales the company generated in the first two months of the year. As more investors learn of SGSI, the shares are likely to begin reflecting a much better valuation, creating a big win for those accumulating shares at current levels.


Disclosure

(Spectrum Global Solutions (SGSI) is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services. )

  293 words
 
 
 
 
 
Big Week for Green Spirit Industries (OTC: GSRX)
 

Last week, Green Spirit Industries (OTC: GSRX) completed its acquisition of a Mendocino-based dispensary and delivery operation: The Green Room. Days before, it announced that its first dispensary in Puerto Rico had begun retail sales.


Why It matters: GSRX now has a piece of two key markets in the budding legal-cannabis industry. The retail dispensary and delivery service in California opens a new line of business for GSRX in the state believed to be the largest cannabis market in the United States. Earlier in March, the company announced a JV with grower/cultivator/extractor Sunset Connect and the acquisition of a majority stake in cannabinoid products manufacturer Spirulinex. Combined with its retail presence, GSRX is proving its ability to deliver on its goal of building a vertically integrated operation in this massive space.


Key Quote: "Green Spirit has now commenced day-to-day operations on the ground in two marketplaces ripe with opportunity: Puerto Rico and California." - Les Ball, CEO


What's Next? Led by Les Ball, former Chairman of Macy's Midwest, GSRX is well-positioned to become a leader in the industry. Recent announcements are probably just the beginning for the Company, which is forecasting $300 million in sales by 2022, with 30% net margins. Achieving just a fraction of that goal could send shares much higher.


Disclosure

(Green Spirit Industries (GSRX) is a client of RedChip Companies. RedChip Companies, Inc. owns 645,000 registered shares of GSRX which it received for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying. )

  212 words
 
 
 
 
 
 
Small-Caps Seen as Safer Bet
 

March saw the first new outflows from ETFs since 2008. A likely result of the massive spike in volatility in February, the outflows where primarily from the large-cap space. In total, there was an estimated $9 billion in redemption from ETFs in March.


Thanks to a turnaround in mid-March, which has led to about $3.7 billion of inflows for small-cap ETFs, the asset class is net positive for the year, up some $1.1 billion.


One reason for the shift, and why it might continue, is that small-caps are often less affected by global macro trends - like tariffs and a trade war with China. Of course, some small-caps are more exposed to these issues, but overall, investors see the space as a safer bet compared to large caps right now, as the data abundantly show.


  134 words
 
 
 
 
Alpine 4 Technologies Ltd. (OTCQB: ALPP) Reveals Latest Acquisition: American Precision Fabricators, Inc. Revenue expected to grow to $67 million annualized by end of 2018
 

Alpine 4 Technologies (OTCQB: ALPP) continued its acquisition strategy with its purchase of American Precision Fabricators Inc. (APF).  This acquisition adds to Alpine 4's tech-manufacturing-sector play, which began in 2016 with its purchase of Quality Circuit Assembly Inc. It also is the fourth acquisition that Alpine 4 has made in two years.


Key Quote: “We're excited about adding APF to the Alpine 4 family.  The addition of APF will a have an immediate impact on Q2 earnings, and APF is expected to have a significant role as a Facilitator in the Alpine 4 umbrellas of companies.”


Why It matters:  Alpine 4’s acquisition of APF will leverage complementary strengths between its subsidiary Quality Circuit Assembly Inc. (QCA) and APF.


QCA currently sends all precision fabrication work for its clientele to other vendors. With the addition of APF, these subsidiaries can cross-leverage complementary services between their customer base. 


Alpine 4 believes this will yield an additional $2.5 million in annual sales between the two companies over the next 18 months.


Backstory: ALPP is a fast-growing technology-driven holding company forecasted to generate $67 million in annualized revenue by FY18; these estimates are driven by adding two new acquisitions (signed LOIs) by 1Q18 with a total forecasted annualized revenue of $43 million, and organic growth of $26 million annualized revenue from their existing subsidiaries.


The goal of the Company is to allow these high-growth subsidiaries to organically develop their own identities and synergistically prosper from inter-company resources, while ALPP has a controlling interest in every subsidiary and has direct control over planning and management.


The Company's portfolio approach provides investors access to unique opportunities with the potential for significant upside while reducing risk through diversification.


Disclosure

(Alpine 4 Technologies (ALPP) is a client of RedChip Companies. ALPP agreed to pay RedChip a monthly cash fee and 400,000 shares of restricted Class A common stock for six months of investor awareness services. )

  282 words
 
 
 
 
 
Pressure BioSciences Inc. (OTCQB: PBIO) Reports Q4 & FY2017 Financial Results; for First Time, Annual Revenue Exceeds $2 Million
 

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry, announced double-digit growth in Q4 and FY17 for its instrument and consumable sales.


The Company generated total revenue of $2.2M in FY17, an increase of 13% YOY, instrument sales increased to $1.5M in FY17, an increase of 21% YOY, and consumables sales increased by 30% YOY in FY17.  


Why It Matters: The recent financial results come as no surprise. Investors following PBIO are aware of the company’s business accomplishments in the last nine months.


A substantial software upgrade for PBIO’s flagship Barocycler 2320EXTREME has brought PCT-based instruments to GMP and GLP compliance, which in turn should open many doors in the biopharmaceutical manufacturing and drug discovery and development areas of the very large life-sciences field.


In February 2018, PBIO announced a two-year, worldwide co-marketing and distribution agreement with ISS Inc., a worldwide leading provider of high-pressure optical-cell systems that can be interfaced directly to PBIO instruments. Synergies between the two systems will generate more revenue growth.


In December 2017, the company announced its acquisition of BaroFold, which specializes in high-pressure technologies. The acquisition drives PBIO into several important areas in biological research and manufacturing.


PBIO's next generation sample preparation instrument received CE Mark approval in February 2017.


Backstory: PBIO's patented PCT platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant, and microbial sources.


The Company has sold some 300 instrument systems worldwide to leading academic, government, biotech and pharma laboratories. Additionally, there have been more than 100 journal articles and peer-reviewed publications on the advantages of PCT technology.


PBIO CEO Richard T. Schumacher is a serial entrepreneur who has founded, operated, and grown biotech and pharma businesses. As president and co-founder of Panacos Pharma, in seven years he helped move the company from a struggling startup to a $700 million market-cap company.


Relative to sales potential, if PBIO can capture just 25% of the market opportunity in mass spectrometry, then we believe it could lead to $75 million in device sales and $36 million in annual recurring revenue. Additional long-term opportunities for PCT exist.


Disclosure

(Pressure BioSciences, Inc. (PBIO) is a client of RedChip Companies, Inc. PBIO agreed to pay RedChip Companies, Inc. a monthly cash fee for 12 months of RedChip investor awareness services.)

  318 words
 
 
 
 
 
 
Esports Entertainment (OTCQB: GMBL) Awards Beta Test Competition Winners
 

Esports Entertainment Group, Inc. (OTCQB: GMBL), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming, announced the winners of its Beta Test Competition on VIE  (https://vie.gg)  the world’s safest, most secure and transparent esports wagering platform.


Why It Matters:In addition to nearly 2000 euros in cash prizes for the top-3 winners, each participant in the beta test received 50 euros. Providing its beta testers with a cash reward should help build some early brand loyalty as GMBL moves forward into its revenue generating growth stage.


Key Quote: As a result of their [beta tester] feedback, we made changes to some of our wagering terminology, boosted our help page with videos, expanded our FAQs and fast tracked future features such as hosting live viewing of actual matches our players are betting on.” – Grant Johnson, CEO


What's Next: GMBL officially launched VIE in late March. With a network of 60+ affiliates to help spread the word, we expect the platform will see strong growth in 2018 and beyond.


Disclosure

(Esports Entertainment Group, Inc. (GMBL) is a client of RedChip Companies, Inc. GMBL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.)

  171 words
 
 
 
 
 
 
Quote of the Week
 
"Get to know management, look for intelligence,
a high level of integrity, strong communication skills,
and make sure they understand their products and business well."

Charles Diker
Diker Management
 
 
 
Lesson of the Week
 
Greg Sichenzia's Advice to Microcap Investors
Read More
 
 
 
 
Latest Video
 
 
 
 
Watch our exclusive interview with Sorrento Therapeutics CEO Dr. Henry Ji. During the interview, Dr. Ji provides insight on the company's growing antibody-centric development pipeline and its significant long-term potential.
 
Watch Now
 
 
 
 
Level Brands: Big Upside Ahead for Major Brand Licensing Operator
 
Watch Now
 
 
 
 
TapImmune: Multiple Clinical Trials Targeting Ovarian and Breast Cancer
 
Watch Now
 
 
 
 
Immuron: Multiple Clinical Trials Underway with Major Near-Term Catalysts
 
Watch Now
 
 
 
 
Catasys: Rapid Expansion of Novel Behavioral Health Treatment Program
 
Watch Now
 
 
 
 
Spectrum Global: Undervalued Small-Cap with Innovative Telecom and Energy Solutions
 
Watch Now
 
 
 
 
Esports Entertainment: Betting on a Winner
 
Watch Now
 
 
 
 
This Week on RedChipTV: Interviews with CEO's of 3 Small-Cap Companies
 
Watch Now
 
 
 
 
Order "Small Stocks, Big Money" Today!
 
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
 
 
MidSouth Week in Review
 
Over the past 20 years only 13% of managers in the large mutual funds beat the index funds
Read More
 
 
 
Recent Reports
 
  • IDXG Fact Sheet: Interpace Diagnostics (NASDAQ: IDXG) is a fully integrated commercial organization that provides clinically useful molecular diagnostic tests and pathology services for evaluating the risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. - March 2018
  • TPIV Fact Sheet: TapImmune (NASDAQ: TPIV) develops immunotherapies targeting tumors and metastatic diseases for a variety of cancers. The Company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer-vaccine approaches. - March 2018
  • IMRN Fact Sheet: Immuron Ltd (NASDAQ: IMRN) is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that can generate a wide range of products, all with a high safety profile. - March 2018
  • DGLY Fact Sheet: Digital Ally® (NASDAQ: DGLY), headquartered in Lenexa, Kan., specializes in the design and manufacture of the highest-quality video-recording equipment and video-analytic software. In industries such as law enforcement, emergency management, commercial fleets, and consumer use, Digital Ally pushes the boundaries of technology. - March 2018
  • CATS Fact Sheet: Catasys Inc. (NASDAQ: CATS) harnesses proprietary big-data predictive analytics, artificial intelligence, and telehealth. These elements, combined with human intervention and integrated, technology-enabled treatment solutions, deliver improved health to members and cost savings to health plans- March 2018
 
 
 
 
Top Movers of the Week
 
INTX led the Nation stocks higher last week, up 52%.
 
 
Weekly Index Performance
 
Major indexes dipped last week, weighed down by under-performing technology stocks.
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
 
RedChip Disclosure
 
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov.